Effect of alternate-day, single-dose, corticosteroid therapy on pituitary-adrenal function.

Carter, M E; James, V. H. T.

doi:10.1136/ard.31.5.379

Cited by 21 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some suggest that delayed release preparations produce less suppression than standard formulations (English et al, 1975), others assert that long acting steroids are more suppressant (Carter & James, 1972) whilst other workers find that standard preparations of prednisolone produce no significant suppression (Turner et al, 1973). Cortisol was also present as a green fluorescent band on the chromatography plate and a technique for estimating cortisol by this means has been devised (Morrison, unpublished observations).…”

Section: Plasma Level Profilesmentioning

confidence: 99%

“…Prednisolone has however been identified as a drug with a high risk of therapeutic inequivalence related to different bioavailability from various formulations (Academy of Pharmaceutical Science, 1973). The employment of alternate-day steroid therapy as a further means of reducing side-effects (Carter & James, 1972) makes reproducible bioavailability essential. Until recently detailed knowledge of the pharmacokinetics of prednisolone has been lacking and dosage regimes have of necessity been arbitrary.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma prednisolone levels from enteric and non‐enteric coated tablets estimated by an original technique.

Morrison¹,

Bradbrook²,

Rogers³

1977

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 A quantitative thin layer chromatographic technique for the estimation of plasma prednisolone levels has been devised with a minimum level of estimation of 10 ng/ml. 2 A comparative study of the absorption of 5 and 10 mg prednisolone from enteric and non‐enteric coated tablets (5 mg) was carried out in healthy subjects. 3 Mean plasma half‐life and peak plasma concentrations obtained from the non‐ enteric coated preparation agree well with previous studies in normal subjects reported by other investigators using competitive protein binding or radioimmunoassay techniques. Intersubject variability in bioavailability was noted. 4 Enteric coating increased the lag time before prednisolone appeared in the blood but did not alter the bioavailability of prednisolone compared to the equivalent dose of the non‐enteric coated tablet.

show abstract

Section: Plasma Level Profilesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plasma prednisolone levels from enteric and non‐enteric coated tablets estimated by an original technique.

Morrison¹,

Bradbrook²,

Rogers³

1977

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…It is well known that continued steroid therapy in children produces retardation of growth (Van Metre, Niermann & Rosen, 1960) and this constitutes a major complication for children who have received a renal transplant (Hulme, Kenyon, Owen, Snell, Mowbray, Porter, Starkie, Muras & Peart, 1972). The introduction of alternate day steroid therapy (Soyka, 1972) produces less growth suppression and causes less suppression of pituitary-adrenal function (Carter & James, 1972). To achieve this, it is essential to avoid long-acting corticosteroids and it is probably desirable to administer the drug as a single dose early on the day of treatment.…”

Section: Introductionmentioning

confidence: 99%

Absorption of enteric and non‐enteric coated prednisolone tablets.

Hulme¹,

James²,

Rault³

1975

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that the degree of suppression may be diminished if the corticosteroid is given intermittently, for instance in a single dose on alternate days or less frequently (Ackerman and Nolan, 1968;Carter and James, 1972;Harter, Reddy, and Thorn, 1963;MacGregor, and others, 1969;Soyka, 1972). Unfortunately, administration less frequently than every day does not always provide satisfactory symptomatic relief, particularly in the treatment of painful conditions such as rheumatoid arthritis (Demos, Krasner, and Groel, 1964).…”

mentioning

confidence: 99%

Single daily dose corticosteroid treatment.

Myles¹,

Schiller²,

Glass³

et al. 1976

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

. (1976). Annals ofthe Rheumatic Diseases, 35,[73][74][75][76]. Single daily dose corticosteroid treatment. Thirteen patients with rheumatoid or psoriatic arthritis who had not previously received corticosteroids were treated with prednisolone in a single dose each morning. Insulin-hypoglycaemia tests were performed before starting steroids in each patient, and again at the conclusion ofthe study in twelve of the thirteen (duration of steroid treatment 8-40 m). There was no difference in the mean basal or peak levels of corticosteroids, or the mean peak of growth hormone (GH) in the tests done before or during treatment, although one patient lost GH responsiveness. There was thus no evidence of hypothalamo-pituitary-adrenal (HPA) suppression in any of the twelve patients, and there was a good therapeutic response in twelve out of thirteen. One patient was dropped from the trial because treatment failed. In contrast, of seven patients who had received a similar total dose of prednisolone twice daily, three showed HPA suppression and two had lost GH responsiveness.

show abstract

Effect of alternate-day, single-dose, corticosteroid therapy on pituitary-adrenal function.

Cited by 21 publications

References 9 publications

Plasma prednisolone levels from enteric and non‐enteric coated tablets estimated by an original technique.

Plasma prednisolone levels from enteric and non‐enteric coated tablets estimated by an original technique.

Absorption of enteric and non‐enteric coated prednisolone tablets.

Single daily dose corticosteroid treatment.

Contact Info

Product

Resources

About